ICP
AZN icon

Interchange Capital Partners’s AstraZeneca AZN Stock Holding History

Interchange Capital Partners’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,947
Closed -$358K – 320
2025
Q4 		$358K Buy
1,947
+339
+21% +$59.5K 0.07% 260
2025
Q3 		$247K Buy
+1,608
New +$243K 0.05% 308
2024
Q4 		– Sell
-1,504
Closed -$235K – 269
2024
Q3 		$235K Sell
1,504
-36
-2% -$5.81K 0.08% 234
2024
Q2 		$240K Buy
+1,540
New +$232K 0.09% 229
2021
Q1 		– Sell
-954
Closed -$95K – 304
2020
Q4 		$95K Buy
+954
New +$101K 0.05% 312

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Interchange Capital Partners's AZN Position: Q1 2026 in Review

Interchange Capital Partners sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 1,947 shares — an estimated $358K sold.

Interchange Capital Partners first reported a position in AZN in Q4 2020 and held it in 5 quarters. The position peaked at $358K in Q4 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Interchange Capital Partners reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
  • Interchange Capital Partners sold 1,947 AstraZeneca shares in Q1 2026, an estimated $358K.
  • Interchange Capital Partners first reported a position in AstraZeneca in Q4 2020 and held it in 5 quarters.
  • Interchange Capital Partners's AstraZeneca position peaked at $358K in Q4 2025.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Interchange Capital Partners's 13F filing for Q1 2026, filed 24 Apr 2026.